Intercept Pharma completes enrollment in late-stage NASH study

Intercept Pharmaceuticals (NASDAQ:ICPT) announces the completion of enrollment in a Phase 3 clinical trial, REVERSE, evaluating obeticholic acid (OCA) in NASH patients with compensated cirrhosis.

The primary endpoint is the proportion of patients achieving at least one-stage histological improvement in fibrosis with no worsening of NASH at month 18 versus placebo.

Participants who complete the double-blind phase will be eligible to enroll in an open-label extension study for up to an additional 12 months.

https://seekingalpha.com/news/3535693-intercept-pharma-completes-enrollment-in-late-stage-nash-study